Ozempic and Wegovy contain the same active ingredient, semaglutide, made by the same manufacturer. Neither is objectively “better” because they’re designed for different purposes: Ozempic is FDA-approved for type 2 diabetes, while Wegovy is approved for weight management and cardiovascular risk reduction. The one that’s right for you depends entirely on your diagnosis and what you’re trying to treat.
Same Drug, Different Approvals
Both medications deliver semaglutide through a weekly injection under the skin. The critical difference is what they’re approved to treat. Ozempic is specifically indicated for improving blood sugar control in adults with type 2 diabetes. Wegovy carries three distinct FDA approvals: chronic weight management in adults and adolescents 12 and older with obesity (or overweight with at least one related health condition), reducing the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease who also have obesity or overweight, and treating a form of fatty liver disease with moderate to advanced scarring.
This distinction matters more than it might seem. Your diagnosis determines which one a doctor can prescribe, which one insurance might cover, and the dose you’ll receive.
The Dosage Difference
Wegovy delivers more semaglutide per injection. Its maintenance dose tops out at 2.4 mg once weekly, while Ozempic maxes out at 2.0 mg once weekly. That 0.4 mg gap is meaningful. The higher dose in Wegovy is what was tested in the large cardiovascular outcomes trial and the weight loss trials, so the clinical evidence for those specific benefits is built around the 2.4 mg level.
Both medications start at low doses and gradually increase over several weeks to reduce side effects. If someone on Ozempic 2.0 mg is being transitioned to Wegovy for weight management, the VA’s conversion guidance recommends moving them directly to the 2.4 mg maintenance dose.
Weight Loss Effectiveness
Both medications cause significant weight loss, but Wegovy’s higher dose produces more of it. Semaglutide works by mimicking a gut hormone that slows digestion, reduces appetite, and changes how the brain processes hunger signals. People taking Ozempic for diabetes do lose weight as a side effect, and the drug has become widely popular for off-label weight loss use. But Wegovy was specifically tested and approved at the dose optimized for that purpose.
Because Ozempic is not FDA-approved for weight management, prescribing it purely for weight loss is considered off-label. That’s legal and common, but it can complicate insurance coverage and means the supporting clinical evidence is less direct than what exists for Wegovy.
Blood Sugar Control
For people with type 2 diabetes, Ozempic is the appropriate choice. Across the SUSTAIN clinical trial program, semaglutide reduced A1c levels (a measure of average blood sugar over roughly three months) by 0.6 to 1.6 percentage points compared to other treatments. That’s a substantial improvement. Wegovy is not approved for diabetes treatment, so prescribing it for blood sugar management would itself be off-label.
Heart Health Benefits
Wegovy has a cardiovascular advantage that Ozempic does not carry on its label. The SELECT trial, published in The Lancet, found that semaglutide at the 2.4 mg dose reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in people with pre-existing heart disease and overweight or obesity who did not have diabetes. This is a Wegovy-specific approval. Ozempic has not been granted a similar cardiovascular indication.
Side Effects at Different Doses
Gastrointestinal problems are the most common complaint with both medications. Nausea, vomiting, diarrhea, and constipation affect a significant portion of users. A meta-analysis in the journal Medicine found that these side effects were elevated across all semaglutide doses compared to placebo.
Interestingly, the same analysis found that lowering the dose within the standard treatment range did not meaningfully reduce stomach-related side effects. In other words, dropping from a higher dose to a slightly lower one may not bring much relief. This suggests the side effect profile between Ozempic and Wegovy is broadly similar, even though Wegovy’s maintenance dose is higher. Most people find that nausea is worst during the dose escalation phase and improves over time.
How the Pens Work
The injection devices differ in a small but practical way. Wegovy uses a single-use pen, meaning each pen contains one pre-measured dose and is discarded after injection. Ozempic uses a multi-use pen that holds several doses, and you dial the correct amount before each injection. Neither approach is inherently better, but some people prefer the simplicity of a pre-filled single-use device, while others like having fewer pens to manage.
Cost and Insurance Coverage
Cost is often the deciding factor. Novo Nordisk, the manufacturer of both drugs, has set the direct-to-consumer cash price for Wegovy and for most Ozempic doses at $349 per month. The highest dose of Ozempic remains at $499 per month for cash-paying patients. New patients can access the two lowest doses of either drug for $199 per month for the first two months.
Insurance coverage, however, is where the real complexity begins. Most private insurance companies and federal health programs do not cover weight loss drugs. Medicare has been explicitly prohibited by law from covering weight loss treatments since 2003. This means Wegovy, approved for weight management, faces steeper coverage barriers than Ozempic, which is covered under diabetes benefits. Many people with type 2 diabetes can get Ozempic covered through their insurance with standard prior authorization, while Wegovy coverage for obesity alone remains inconsistent.
This coverage gap is a major reason Ozempic became so popular for off-label weight loss. Some doctors prescribe it because patients can actually afford it through their diabetes coverage, even when the primary goal is losing weight. That workaround has insurance and ethical complications, but it reflects the reality of the current system.
Which One Should You Use
If you have type 2 diabetes, Ozempic is the straightforward choice. It’s approved for your condition, likely covered by insurance, and effective at both lowering blood sugar and producing weight loss as a secondary benefit.
If your primary concern is weight loss without diabetes, Wegovy is the clinically appropriate option. It’s dosed higher, tested specifically for that purpose, and carries the cardiovascular risk reduction data to support it. The challenge is getting it covered.
If you have both type 2 diabetes and obesity, the decision gets more nuanced and depends on which condition your doctor prioritizes, what your insurance covers, and whether the cardiovascular benefits of the 2.4 mg dose matter for your risk profile. You cannot take both medications at the same time, as the FDA specifically advises against combining semaglutide products or using them alongside other drugs in the same class.